Emerging & New Technologies in Drug Development

In recent decades there has been a dramatic increase in ocular imaging technologies—both for the anterior and posterior segments. This has been largely to the result of increased computer processing power, as applied to hardware control and data analysis. The technologies required to deliver agents specifically and effectively to the eye are rapidly evolving. These technologies will have the potential to radically alter the way many diseases are treated.

The market for potential new technologies is significant; the global pharmaceutical market was estimated at $18.1 billion at year end 2013 and is estimated to grow to approximately $23 billion by year end 2018. Within this time period, retinal pharmaceuticals are demonstrating the greatest growth, from $6.9 billion to $9.9 billion.*

Ophthalmic Drugs will enable you to gain insight from 4 top pharma companies to discuss the current regulatory landscape of emerging technologies, explore the applications of blockchain in drug development and examine succesful trials that generate data on efficacy and costs of the technologies, as well as the long-term impacts for various conditions; traditional trial designs versus current.

Not only this, poor patient compliance is a major impediment to effective treatments in eye care. By bringing in new technologies will help ease the situation and enable patients to become comfortable during treatment. Also, monitoring systems for clinical trials are a revolutionary method to ease work of clinicians and make clinical data more reliable. Other factors will also be discussed at Ophthalmic Drugs, including novel drug delivery systems and how they can contribute to patient adherence, which have been approved by the FDA.

Envisia Therapeutics has leveraged 3-D printing technology developed in the microelectronics industry to create customized delivery vehicles for prostaglandins and other ophthalmic agents.* Hear more from Envisia Therapeutics as they open day 2 of Ophthalmic Drugs, to discuss nanotechnology technology for glaucoma, cataract, AMD and DME.

Further information is available at: www.ophthalmicdrugs.com/phpr

For those looking to attend there is currently a £100 early-bird saving by October 31st

SMi Presents the Launch of…
Ophthalmic Drugs
Date: 28th – 29th November 2017
Location: Kensington, London
Website: www.ophthalmicdrugs.com/phpr

Sponsored by: Leica Microsystems | Experimentica

—end—

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk